Literature DB >> 10216063

Significance of serum antibodies reactive with flavoprotein subunit of succinate dehydrogenase in thyroid associated orbitopathy.

B M Hosal1, J K Swanson, C R Thompson, S Kubota, K Gunji, J S Kennerdell, J R Wall.   

Abstract

AIMS: Thyroid associated orbitopathy (TAO) is an autoimmune disorder of extraocular muscles and orbital connective tissue. Identification of the principal target antigens would help the understanding of the pathogenesis of the disease and possibly lead to the development of specific therapies in the future. The purpose of this study was to measure serum antibodies against the flavoprotein subunit of succinate dehydrogenase in patients with TAO and correlate their presence with factors of TAO.
METHODS: Sera of patients with active TAO of 6 months' duration or less were tested for antibodies against the flavoprotein subunit of succinate dehydrogenase. Clinical data were obtained by retrospective review of patients' charts. Enzyme linked immunosorbent assay was used to test sera for serum antibodies against purified succinate dehydrogenase.
RESULTS: 38 patients with TAO and 32 healthy age and sex matched controls were included in the study. Anti-flavoprotein antibodies were detected in 24 out of 38 patients with TAO (63.16%) and in five out of 32 healthy controls (15.63%) (p<0.01). Neither age, sex, duration of thyroid disease, thyroid status, treatment of thyroid disease, smoking history, duration of orbitopathy, activity of orbitopathy, nor the presence of lid retraction were significantly associated with the presence of serum anti-flavoprotein antibodies (p>0.05). However, the total number of rectus muscles affected in both eyes of the patients was significantly correlated with the finding of a positive antibody test (p<0.05).
CONCLUSIONS: Serum antibodies reactive with the flavoprotein subunit of succinate dehydrogenase are associated with extraocular muscle involvement in active TAO of recent onset.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10216063      PMCID: PMC1723051          DOI: 10.1136/bjo.83.5.605

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  21 in total

Review 1.  Extrathyroidal complications of Graves' disease.

Authors:  A P Weetman
Journal:  Q J Med       Date:  1993-08

Review 2.  Nuclear localization of autoantibodies. Novel insights into protein translocation and cellular function.

Authors:  M P Madaio; K Yanase; M H Foster; R M Smith; T K Emmons; M Fabbi; A Puccetti; L Jarett
Journal:  Ann N Y Acad Sci       Date:  1997-04-05       Impact factor: 5.691

3.  The 64-kilodalton eye muscle protein is the flavoprotein subunit of mitochondrial succinate dehydrogenase: the corresponding serum antibodies are good markers of an immune-mediated damage to the eye muscle in patients with Graves' hyperthyroidism.

Authors:  S Kubota; K Gunji; B A Ackrell; B Cochran; C Stolarski; S Wengrowicz; J S Kennerdell; Y Hiromatsu; J Wall
Journal:  J Clin Endocrinol Metab       Date:  1998-02       Impact factor: 5.958

4.  The association of cigarette smoking with clinical subtypes of ophthalmic Graves' disease.

Authors:  W R Nunery; R T Martin; G W Heinz; T J Gavin
Journal:  Ophthalmic Plast Reconstr Surg       Date:  1993-06       Impact factor: 1.746

5.  Quality of life in patients with Graves' ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument.

Authors:  M N Gerding; C B Terwee; F W Dekker; L Koornneef; M F Prummel; W M Wiersinga
Journal:  Thyroid       Date:  1997-12       Impact factor: 6.568

6.  Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.

Authors:  L Bartalena; C Marcocci; F Bogazzi; L Manetti; M L Tanda; E Dell'Unto; G Bruno-Bossio; M Nardi; M P Bartolomei; A Lepri; G Rossi; E Martino; A Pinchera
Journal:  N Engl J Med       Date:  1998-01-08       Impact factor: 91.245

7.  T cell responses to orbital antigens in thyroid-associated ophthalmopathy.

Authors:  K Arnold; N Tandon; R S McIntosh; R Elisei; M Ludgate; A P Weetman
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

Review 8.  Medical management of Graves' ophthalmopathy.

Authors:  M F Prummel; W M Wiersinga
Journal:  Thyroid       Date:  1995-06       Impact factor: 6.568

9.  The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: prognostic factors and the role of methimazole.

Authors:  A W Kung; C C Yau; A Cheng
Journal:  J Clin Endocrinol Metab       Date:  1994-08       Impact factor: 5.958

Review 10.  The ocular muscle cell is a target of the immune system in endocrine ophthalmopathy.

Authors:  J I Kiljanski; V Nebes; J R Wall
Journal:  Int Arch Allergy Immunol       Date:  1995-03       Impact factor: 2.749

View more
  1 in total

Review 1.  Eye muscle antibodies in Graves' ophthalmopathy: pathogenic or secondary epiphenomenon?

Authors:  T Mizokami; M Salvi; J R Wall
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.